{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T06:43:53Z","timestamp":1725432233673},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1093\/carcin\/bgi103","type":"journal-article","created":{"date-parts":[[2005,4,29]],"date-time":"2005-04-29T00:13:24Z","timestamp":1114733604000},"page":"1542-1552","source":"Crossref","is-referenced-by-count":11,"title":["Tamoxifen resistance and Her2\/neu expression in an aged, irradiated rat breast carcinoma model"],"prefix":"10.1093","volume":"26","author":[{"given":"Norman C.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Servinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archie","family":"Christian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Dicello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Huso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,4,28]]},"reference":[{"key":"key\n\t\t\t\t20171011212829_B1","doi-asserted-by":"crossref","unstructured":"Bhatia,S., Robison,L.L., Oberlin,O., Greenberg,M., Bunin,G., Fossati-Bellani,F. and Meadows,A.T. ( 1996 ) Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. , 334 , 745 \u2013751.","DOI":"10.1056\/NEJM199603213341201"},{"key":"key\n\t\t\t\t20171011212829_B2","doi-asserted-by":"crossref","unstructured":"Bhatia,S., Yasui,Y., Robison,L.L. et al . ( 2003 ) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J. Clin. Oncol. , 21 , 4386 \u20134394.","DOI":"10.1200\/JCO.2003.11.059"},{"key":"key\n\t\t\t\t20171011212829_B3","doi-asserted-by":"crossref","unstructured":"van Leeuwen,F.E., Klokman,W.J., Stovall,M., Dahler,E.C., van't Veer,M.B., Noordijk,E.M., Crommelin,M.A., Aleman,B.M., Broeks,A., Gospodarowicz,M., Travis,L.B. and Russell,N.S. ( 2003 ) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J. Natl Cancer Inst. , 95 , 971 \u2013980.","DOI":"10.1093\/jnci\/95.13.971"},{"key":"key\n\t\t\t\t20171011212829_B4","unstructured":"Peto,R. ( 2000 ) Adjuvant hormone therapy: tamoxifen. In Proceedings of the NIH Consensus Development Conference: Adjuvant Therapy for Breast Cancer , November 1\u20133, 2000, Bethesda, MD."},{"key":"key\n\t\t\t\t20171011212829_B5","doi-asserted-by":"crossref","unstructured":"Tamoxifen for early breast cancer: an overview of the randomised trials. ( 1998 ) Early Breast Cancer Trialists' Collaborative Group. Lancet , 351 , 1451 \u20131467.","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"key\n\t\t\t\t20171011212829_B6","doi-asserted-by":"crossref","unstructured":"Borg,A., Baldetorp,B., Ferno,M., Killander,D., Olsson,H., Ryden,S. and Sigurdsson,H. ( 1994 ) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. , 81 , 137 \u2013144.","DOI":"10.1016\/0304-3835(94)90194-5"},{"key":"key\n\t\t\t\t20171011212829_B7","doi-asserted-by":"crossref","unstructured":"Leitzel,K., Teramoto,Y., Konrad,K., Chinchilli,V.M., Volas,G., Grossberg,H., Harvey,H., Demers,L. and Lipton,A. ( 1995 ) Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. , 13 , 1129 \u20131135.","DOI":"10.1200\/JCO.1995.13.5.1129"},{"key":"key\n\t\t\t\t20171011212829_B8","doi-asserted-by":"crossref","unstructured":"Houston,S.J., Plunkett,T.A., Barnes,D.M., Smith,P., Rubens,R.D. and Miles,D.W. ( 1999 ) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer , 79 , 1220 \u20131226.","DOI":"10.1038\/sj.bjc.6690196"},{"key":"key\n\t\t\t\t20171011212829_B9","doi-asserted-by":"crossref","unstructured":"Benz,C.C., Scott,G.K., Sarup,J.C., Johnson,R.M., Tripathy,D., Coronado,E., Shepard,H.M. and Osborne,C.K. ( 1993 ) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu. Breast Cancer Res. Treat. , 24 , 85 \u201395.","DOI":"10.1007\/BF01961241"},{"key":"key\n\t\t\t\t20171011212829_B10","unstructured":"Pietras,R.J., Arboleda,J., Reese,D.M., Wongvipat,N., Pegram,M.D., Ramos,L., Gorman,C.M., Parker,M.G., Sliwkowski,M.X. and Slamon,D.J. ( 1995 ) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene , 10 , 2435 \u20132446."},{"key":"key\n\t\t\t\t20171011212829_B11","doi-asserted-by":"crossref","unstructured":"Osborne,C.K., Bardou,V., Hopp,T.A., Chamness,G.C., Hilsenbeck,S.G., Fuqua,S.A., Wong,J., Allred,D.C., Clark,G.M. and Schiff,R. ( 2003 ) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst. , 95 , 353 \u2013361.","DOI":"10.1093\/jnci\/95.5.353"},{"key":"key\n\t\t\t\t20171011212829_B12","doi-asserted-by":"crossref","unstructured":"Baselga,J. ( 2001 ) Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer , 37(Suppl. 1) , S18 \u2013S24.","DOI":"10.1016\/S0959-8049(00)00404-4"},{"key":"key\n\t\t\t\t20171011212829_B13","doi-asserted-by":"crossref","unstructured":"Park,B.W., Zhang,H.T., Wu,C., Berezov,A., Zhang,X., Dua,R., Wang,Q., Kao,G., O'Rourke,D.M., Greene,M.I. and Murali,R. ( 2000 ) Rationally designed anti-HER2\/neu peptide mimetic disables P185HER2\/neu tyrosine kinases in vitro and in vivo . Nat. Biotechnol. , 18 , 194 \u2013198.","DOI":"10.1038\/72651"},{"key":"key\n\t\t\t\t20171011212829_B14","doi-asserted-by":"crossref","unstructured":"Berezov,A., Chen,J., Liu,Q., Zhang,H.T., Greene,M.I. and Murali,R. ( 2002 ) Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. , 277 , 28330 \u201328339.","DOI":"10.1074\/jbc.M202880200"},{"key":"key\n\t\t\t\t20171011212829_B15","doi-asserted-by":"crossref","unstructured":"Xiong,H.Q. and Abbruzzese,J.L. ( 2002 ) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. , 29 , 31 \u201337.","DOI":"10.1053\/sonc.2002.35645"},{"key":"key\n\t\t\t\t20171011212829_B16","doi-asserted-by":"crossref","unstructured":"Baselga,J., Rischin,D., Ranson,M. et al . ( 2002 ) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. , 20 , 4292 \u20134302.","DOI":"10.1200\/JCO.2002.03.100"},{"key":"key\n\t\t\t\t20171011212829_B17","unstructured":"Jolicoeur,P., Bouchard,L., Guimond,A., Ste-Marie,M., Hanna,Z. and Dievart,A. ( 1998 ) Use of mouse mammary tumour virus (MMTV)\/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development. Biochem. Soc. Symp. , 63 , 159 \u2013165."},{"key":"key\n\t\t\t\t20171011212829_B18","doi-asserted-by":"crossref","unstructured":"Bouchard,L., Lamarre,L., Tremblay,P.J. and Jolicoeur,P. ( 1989 ) Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV\/c-neu oncogene. Cell , 57 , 931 \u2013936.","DOI":"10.1016\/0092-8674(89)90331-0"},{"key":"key\n\t\t\t\t20171011212829_B19","unstructured":"Wang,B., Kennan,W.S., Yasukawa-Barnes,J., Lindstrom,M.J. and Gould,M.N. ( 1991 ) Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res. , 51 , 5649 \u20135654."},{"key":"key\n\t\t\t\t20171011212829_B20","unstructured":"Wang,B., Kennan,W.S., Yasukawa-Barnes,J., Lindstrom,M.J. and Gould,M.N. ( 1992 ) Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. Cancer Res. , 52 , 4102 \u20134105."},{"key":"key\n\t\t\t\t20171011212829_B21","doi-asserted-by":"crossref","unstructured":"Gould,M.N. ( 1993 ) The introduction of activated oncogenes to mammary cells in vivo using retroviral vectors: a new model for the chemoprevention of premalignant and malignant lesions of the breast. J. Cell. Biochem. Suppl. , 17G , 66 \u201372.","DOI":"10.1002\/jcb.240531113"},{"key":"key\n\t\t\t\t20171011212829_B22","doi-asserted-by":"crossref","unstructured":"Davies,B.R., Warren,J.R., Schmidt,G. and Rudland,P.S. ( 1998 ) Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats. Biochem. Soc. Symp. , 63 , 167 \u2013184.","DOI":"10.1042\/bst0260167"},{"key":"key\n\t\t\t\t20171011212829_B23","doi-asserted-by":"crossref","unstructured":"Watson,P.A., Kim,K., Chen,K.S. and Gould,M.N. ( 2002 ) Androgen-dependent mammary carcinogenesis in rats transgenic for the Neu proto -oncogene. Cancer Cell , 2 , 67 \u201379.","DOI":"10.1016\/S1535-6108(02)00083-1"},{"key":"key\n\t\t\t\t20171011212829_B24","doi-asserted-by":"crossref","unstructured":"Gould,M.N. ( 1995 ) Rodent models for the study of etiology, prevention and treatment of breast cancer. Semin. Cancer Biol. , 6 , 147 \u2013152.","DOI":"10.1006\/scbi.1995.0023"},{"key":"key\n\t\t\t\t20171011212829_B25","doi-asserted-by":"crossref","unstructured":"Gillette,C.A., Zhu,Z., Westerlind,K.C., Melby,C.L., Wolfe,P. and Thompson,H.J. ( 1997 ) Energy availability and mammary carcinogenesis: effects of calorie restriction and exercise. Carcinogenesis , 18 , 1183 \u20131188.","DOI":"10.1093\/carcin\/18.6.1183"},{"key":"key\n\t\t\t\t20171011212829_B26","doi-asserted-by":"crossref","unstructured":"Zan,Y., Haag,J.D., Chen,K.S., Shepel,L.A. et al . ( 2003 ) Production of knockout rats using ENU mutagenesis and a yeast-based screening assay. Nat. Biotechnol. , 21 , 645 \u2013651.","DOI":"10.1038\/nbt830"},{"key":"key\n\t\t\t\t20171011212829_B27","doi-asserted-by":"crossref","unstructured":"Welsch,C.W., Goodrich-Smith,M., Brown,C.K., Miglorie,N. and Clifton,K.H. ( 1981 ) Effect of an estrogen antagonist (tamoxifen) on the initiation and progression of gamma-irradiation-induced mammary tumors in female Sprague-Dawley rats. Eur. J. Cancer Clin. Oncol. , 17 , 1255 \u20131258.","DOI":"10.1016\/0014-2964(81)90004-9"},{"key":"key\n\t\t\t\t20171011212829_B28","doi-asserted-by":"crossref","unstructured":"Gotoh,T., Yamada,K., Ito,A., Yin,H., Kataoka,T. and Dohi,K. ( 1998 ) Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn. J. Cancer Res. , 89 , 487 \u2013495.","DOI":"10.1111\/j.1349-7006.1998.tb03288.x"},{"key":"key\n\t\t\t\t20171011212829_B29","doi-asserted-by":"crossref","unstructured":"Thordarson,G., Lee,A.V., McCarty,M., Van Horn,K., Chu,O., Chou,Y.C., Yang,J., Guzman,R.C., Nandi,S. and Talamantes,F. ( 2001 ) Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. Carcinogenesis , 22 , 2039 \u20132047.","DOI":"10.1093\/carcin\/22.12.2039"},{"key":"key\n\t\t\t\t20171011212829_B30","doi-asserted-by":"crossref","unstructured":"Rodriguez-Burford,C., Lubet,R.A., Steele,V.E., Eto,I., Bandy,M., Juliana,M.M., Weiss,H.L., Grizzle,W.E., Kelloff,G.J. and Grubbs,C.J. ( 2001 ) Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. Oncol. Rep. , 8 , 373 \u2013379.","DOI":"10.3892\/or.8.2.373"},{"key":"key\n\t\t\t\t20171011212829_B31","doi-asserted-by":"crossref","unstructured":"Drebin,J.A., Link,V.C., Weinberg,R.A. and Greene,M.I. ( 1986 ) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl Acad. Sci. USA , 83 , 9129 \u20139133.","DOI":"10.1073\/pnas.83.23.9129"},{"key":"key\n\t\t\t\t20171011212829_B32","doi-asserted-by":"crossref","unstructured":"Buzard,G.S., Enomoto,T., Anderson,L.M., Perantoni,A.O., Devor,D.E. and Rice,J.M. ( 1999 ) Activation of neu by missense point mutation in the transmembrane domain in schwannomas induced in C3H\/HeNCr mice by transplacental exposure to N-nitrosoethylurea. J. Cancer Res. Clin. Oncol. , 125 , 653 \u2013659.","DOI":"10.1007\/s004320050330"},{"key":"key\n\t\t\t\t20171011212829_B33","doi-asserted-by":"crossref","unstructured":"Denizot,F. and Lang,R. ( 1986 ) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods , 89 , 271 \u2013277.","DOI":"10.1016\/0022-1759(86)90368-6"},{"key":"key\n\t\t\t\t20171011212829_B34","doi-asserted-by":"crossref","unstructured":"Costa,I., Solanas,M. and Escrich,E. ( 2002 ) Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors. Arch. Pathol. Lab. Med. , 126 , 915 \u2013927.","DOI":"10.5858\/2002-126-0915-HCOMNL"},{"key":"key\n\t\t\t\t20171011212829_B35","doi-asserted-by":"crossref","unstructured":"Shan,L., Yu,M. and Snyderwine,E.G. ( 2005 ) Gene expression profiling of chemically induced rat mammary gland cancer. Carcinogenesis , 26 , 503 \u2013509.","DOI":"10.1093\/carcin\/bgh330"},{"key":"key\n\t\t\t\t20171011212829_B36","unstructured":"Wada,T., Myers,J.N., Kokai,Y., Brown,V.I., Hamuro,J., LeVea,C.M. and Greene,M.I. ( 1990 ) Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene , 5 , 489 \u2013495."},{"key":"key\n\t\t\t\t20171011212829_B37","doi-asserted-by":"crossref","unstructured":"Fasco,M.J., Keyomarsi,K., Arcaro,K.F. and Gierthy,J.F. ( 2000 ) Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol. Cell Endocrinol. , 162 , 167 \u2013180.","DOI":"10.1016\/S0303-7207(00)00194-5"},{"key":"key\n\t\t\t\t20171011212829_B38","unstructured":"Leygue,E., Dotzlaw,H., Watson,P.H. and Murphy,L.C. ( 1998 ) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. , 58 , 3197 \u20133201."},{"key":"key\n\t\t\t\t20171011212829_B39","unstructured":"Fuqua,S.A., Schiff,R., Parra,I., Friedrichs,W.E., Su,J.L., McKee,D.D., Slentz-Kesler,K., Moore,L.B., Willson,T.M. and Moore,J.T. ( 1999 ) Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. , 59 , 5425 \u20135428."},{"key":"key\n\t\t\t\t20171011212829_B40","unstructured":"Drebin,J.A., Link,V.C. and Greene,M.I. ( 1988 ) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo . Oncogene , 2 , 387 \u2013394."},{"key":"key\n\t\t\t\t20171011212829_B41","doi-asserted-by":"crossref","unstructured":"Lemon,H.M., Kumar,P.F., Peterson,C., Rodriguez-Sierra,J.F. and Abbo,K.M. ( 1989 ) Inhibition of radiogenic mammary carcinoma in rats by estriol of tamoxifen. Cancer , 63 , 1685 \u20131692.","DOI":"10.1002\/1097-0142(19900501)63:9<1685::AID-CNCR2820630907>3.0.CO;2-X"},{"key":"key\n\t\t\t\t20171011212829_B42","unstructured":"Dowsett,M., Harper-Wynne,C., Boeddinghaus,I., Salter,J., Hills,M., Dixon,M., Ebbs,S., Gui,G., Sacks,N. and Smith,I. ( 2001 ) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. , 61 , 8452 \u20138458."},{"key":"key\n\t\t\t\t20171011212829_B43","unstructured":"Kumar,R., Mandal,M., Lipton,A., Harvey,H. and Thompson,C.B. ( 1996 ) Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin. Cancer Res. , 2 , 1215 \u20131219."},{"key":"key\n\t\t\t\t20171011212829_B44","doi-asserted-by":"crossref","unstructured":"Bartsch,C., Szadowska,A., Karasek,M., Bartsch,H., Geppert,M. and Mecke,D. ( 2000 ) Serial transplants of DMBA-induced mammary tumors in fischer rats as model system for human breast cancer: V. myoepithelial-mesenchymal conversion during passaging as possible cause for modulation of pineal-tumor interaction. Exp. Toxicol. Pathol. , 52 , 93 \u2013101.","DOI":"10.1016\/S0940-2993(00)80091-3"},{"key":"key\n\t\t\t\t20171011212829_B45","doi-asserted-by":"crossref","unstructured":"Encarnacion,C.A., Ciocca,D.R., McGuire,W.L., Clark,G.M., Fuqua,S.A. and Osborne,C.K. ( 1993 ) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. , 26 , 237 \u2013246.","DOI":"10.1007\/BF00665801"},{"key":"key\n\t\t\t\t20171011212829_B46","doi-asserted-by":"crossref","unstructured":"Tonetti,D.A. and Jordan,V.C. ( 1997 ) The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J. Steroid Biochem. Mol. Biol. , 62 , 119 \u2013128.","DOI":"10.1016\/S0960-0760(97)00034-4"},{"key":"key\n\t\t\t\t20171011212829_B47","unstructured":"Zhang,Q.X., Borg,A., Wolf,D.M., Oesterreich,S. and Fuqua,S.A. ( 1997 ) An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. , 57 , 1244 \u20131249."},{"key":"key\n\t\t\t\t20171011212829_B48","unstructured":"Yao,K., Lee,E.S., Bentrem,D.J., England,G., Schafer,J.I., O'Regan,R.M. and Jordan,V.C. ( 2000 ) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. , 6 , 2028 \u20132036."},{"key":"key\n\t\t\t\t20171011212829_B49","doi-asserted-by":"crossref","unstructured":"Poola,I. and Speirs,V. ( 2001 ) Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J. Steroid Biochem. Mol. Biol. , 78 , 459 \u2013469.","DOI":"10.1016\/S0960-0760(01)00118-2"},{"key":"key\n\t\t\t\t20171011212829_B50","doi-asserted-by":"crossref","unstructured":"Chaidarun,S.S. and Alexander,J.M. ( 1998 ) A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression. Mol. Endocrinol. , 12 , 1355 \u20131366.","DOI":"10.1210\/mend.12.9.0170"},{"key":"key\n\t\t\t\t20171011212829_B51","doi-asserted-by":"crossref","unstructured":"Leygue,E., Dotzlaw,H., Watson,P.H. and Murphy,L.C. ( 2000 ) Altered expression of estrogen receptor-alpha variant messenger RNAs between adjacent normal breast and breast tumor tissues. Breast Cancer Res. , 2 , 64 \u201372.","DOI":"10.1186\/bcr30"},{"key":"key\n\t\t\t\t20171011212829_B52","doi-asserted-by":"crossref","unstructured":"Zhang,H., Wang,Q., Montone,K.T., Peavey,J.E., Drebin,J.A., Greene,M.I. and Murali,R. ( 1999 ) Shared antigenic epitopes and pathobiological functions of anti-p185(her2\/neu) monoclonal antibodies. Exp. Mol. Pathol. , 67 , 15 \u201325.","DOI":"10.1006\/exmp.1999.2266"},{"key":"key\n\t\t\t\t20171011212829_B53","unstructured":"Kurokawa,H., Lenferink,A.E., Simpson,J.F., Pisacane,P.I., Sliwkowski,M.X., Forbes,J.T. and Arteaga,C.L. ( 2000 ) Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. , 60 , 5887 \u20135894."},{"key":"key\n\t\t\t\t20171011212829_B54","doi-asserted-by":"crossref","unstructured":"Witters,L., Engle,L. and Lipton,A. ( 2002 ) Restoration of estrogen responsiveness by blocking the HER-2\/neu pathway. Oncol. Rep. , 9 , 1163 \u20131166.","DOI":"10.3892\/or.9.6.1163"},{"key":"key\n\t\t\t\t20171011212829_B55","unstructured":"Baselga,J. ( 2000 ) Current and planned clinical trials with trastuzumab (Herceptin). Semin. Oncol. , 27 , 27 \u201332."},{"key":"key\n\t\t\t\t20171011212829_B56","unstructured":"Reilly,R.T., Machiels,J.P., Emens,L.A., Ercolini,A.M., Okoye,F.I., Lei,R.Y., Weintraub,D. and Jaffee,E.M. ( 2001 ) The collaboration of both humoral and cellular HER-2\/neu-targeted immune responses is required for the complete eradication of HER-2\/neu-expressing tumors. Cancer Res. , 61 , 880 \u2013883."},{"key":"key\n\t\t\t\t20171011212829_B57","doi-asserted-by":"crossref","unstructured":"Knutson,K.L., Schiffman,K. and Disis,M.L. ( 2001 ) Immunization with a HER-2\/neu helper peptide vaccine generates HER-2\/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. , 107 , 477 \u2013484.","DOI":"10.1172\/JCI11752"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/26\/9\/1542\/7089474\/bgi103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T04:56:01Z","timestamp":1625892961000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/carcin\/article\/26\/9\/1542\/2390922\/Tamoxifen-resistance-and-Her2neu-expression-in-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,28]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,4,28]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgi103","relation":{},"ISSN":["1460-2180","0143-3334"],"issn-type":[{"value":"1460-2180","type":"electronic"},{"value":"0143-3334","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,9]]},"published":{"date-parts":[[2005,4,28]]}}}